Firyal Kryou new CFO for Calmark

Calmark Sweden AB (publ) announces today that the company has contracted Firyal Kryou as interim CFO and member of the management team. She will take up the role today, December 1, 2021.

Firyal Kryou, born in 1972, has long and broad experience from many different industries such as telecom, real estate, retail, e-commerce and construction. Firyal Kryou has solid experience in business planning, change management, negotiation, project management, HR consulting and coaching. Firyal has worked as self-employed since 2018 and has, among other things, run change projects to structure and improve processes and routines at international companies.

"In the commercialization phase that Calmark is in, with a strong focus on international expansion, we will benefit greatly from the broad experience Firyal has," says Anna Söderlund, CEO of Calmark. "I'm very happy to welcome her to the team!"

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.